Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders.
The last earnings update was 115 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Bioasis Technologies. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Bioasis Technologies's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioasis Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Bioasis Technologies's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Bioasis Technologies's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Bioasis Technologies's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if Bioasis Technologies is high growth as no earnings estimate data is available.
Unable to determine if Bioasis Technologies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Bioasis Technologies's filings and announcements here.
Bioasis Technologies's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Bioasis Technologies's finances.
The net worth of a company is the difference between its assets and liabilities.
Bioasis Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Bioasis Technologies's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Bioasis Technologies's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Bioasis Technologies has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Deborah Ann Rathjen, B.Sc. (Hons.), Ph.D., M.A.I.C.D., FTSE, Q.C. has been the President and Chief Executive Officer of Bioasis Technologies Inc. since March 11, 2019. Dr. Rathjen served as the Chief Executive Officer of Bionomics Limited from November 09, 2018 to January 31, 2019. Dr. Rathjen was an Executive Director at Bionomics Ltd. from May 18, 2000 to November 09, 2018. She was Managing Director of Bionomics Limited until November 9, 2018. Dr. Rathjen has proven to be a skilled dealmaker and builder of alliances with her work on the Bionomics and Merck collaborations related to Alzheimer's disease and other neurodegenerative and psychiatric diseases with the goal to improve cognitive dysfunction in neurodegeneration. She has significant experience in company building and financing, mergers and acquisitions, therapeutic product research and development, business development, licensing and commercialization. She has experience in research, business development and licensing and licensing and has licensed a range of products including drug delivery technologies, diagnostics, new therapeutics and cosmetic products. Dr. Rathjen joined Bionomics in June 2000 from Peptech Limited, where she was General Manager of Business Development and Licensing. She also serves as Chief Executive Officer at Prestwick Chemical, Inc. since October 2014. Dr. Rathjen was a co-inventor of Peptech's TNF technology and leader of its successful Defense of its key TNF patents against a legal challenge by BASF, providing Peptech with a strong commercial basis for licensing negotiations with BASF, Centocor and other companies with anti-TNF products. Dr. Rathjen is an expert in the field of cell biology with specific expertise in inflammation and cancer. She serves as Executive Chair of Bioasis Technologies Inc. since December 10, 2018. She served as Chair of the Board of biOasis Technologies Inc. since March 21, 2018 until December 10, 2018 and as its Director since September 21, 2017. Dr. Rathjen is a member of the Federal Government's Australian Biotechnology Advisory Council and the Prime Minister's Science Engineering and Innovation Council. In 2004, she was awarded the AusBiotech President’s Medal for her significant contribution to the Australian biotechnology industry. In 2006 Dr. Rathjen received a Distinguished Alumni Award from Flinders University, in 2009 the BioSingapore Asia Pacific Woman Entrepreneur of the Year, 2010 Bio Innovation SA Industry Leader Award, BioSpectrum Asia Person of the Year 2013 and in 2014 the Life Science Woman of the Year. Dr. Rathjen received her doctor of philosophy degree in immunology from Macquarie University in Sydney, Australia and her bachelor of science degree in immunology from Flinders University in Adelaide, Australia.
Insufficient data for Deborah to compare compensation growth.
Deborah's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Bioasis Technologies management team is less than 2 years, this suggests a new team.
Chief Financial Officer
Director of Investor Relations
Director of Marketing
Executive VP & Chief Business Officer
VP & Head of External Research
Senior VP & Head of Research & Development Operations
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Bioasis Technologies board of directors is less than 3 years, this suggests a new board.
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company’s lead program is xB3-001, an xB3 peptide vector-trastuzumab fusion. It is developing xB3, a proprietary platform technology for the delivery of therapeutics and imaging agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders in the areas of high unmet medical needs, including brain cancers, and metabolic and neurodegenerative diseases. The company’s in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain metastases, glioblastomas, and neurodegenerative diseases. Bioasis Technologies Inc. has a collaborative research agreement with CQDM and Brain Canada to perform research on the delivery of therapeutic compounds across the BBB; and a strategic collaboration with BIOAGILYTIX for the development and validation of bioanalytical methods to support the xB3 TM-001 program, as well with WuXi Biologics (Hong Kong) Limited for the development and manufacturing of xB3-001 to treat cancer. The company was incorporated in 2006 and is headquartered in Guilford, Connecticut.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.